Afstyla Purple Book BLA 125591

BLA number
125591
Proprietary names
Afstyla
Proper names
Antihemophilic Factor (Recombinant), Single Chain
Applicant
CSL Behring Lengnau AG
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001AfstylaAntihemophilic Factor (Recombinant), Single Chain351(a)3000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-05-25
002AfstylaAntihemophilic Factor (Recombinant), Single Chain351(a)1000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-05-25
003AfstylaAntihemophilic Factor (Recombinant), Single Chain351(a)250IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-05-25
004AfstylaAntihemophilic Factor (Recombinant), Single Chain351(a)2000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-05-25
005AfstylaAntihemophilic Factor (Recombinant), Single Chain351(a)500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-05-25
006AfstylaAntihemophilic Factor (Recombinant), Single Chain351(a)2500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2017-03-31
007AfstylaAntihemophilic Factor (Recombinant), Single Chain351(a)1500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2017-03-31

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-06-01U001Afstyla351(a)RxCSL Behring Lengnau AG
2023-06-01U002Afstyla351(a)RxCSL Behring Lengnau AG
2023-06-01U003Afstyla351(a)RxCSL Behring Lengnau AG
2023-06-01U004Afstyla351(a)RxCSL Behring Lengnau AG
2023-06-01U005Afstyla351(a)RxCSL Behring Lengnau AG
2023-06-01U006Afstyla351(a)RxCSL Behring Lengnau AG
2023-06-01U007Afstyla351(a)RxCSL Behring Lengnau AG
2021-05-01U001Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2021-05-01U002Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2021-05-01U003Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2021-05-01U004Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2021-05-01U005Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2021-05-01U006Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2021-05-01U007Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2020-08-01R001Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2020-08-01R002Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2020-08-01R003Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2020-08-01R004Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2020-08-01R005Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2020-08-01R006Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG
2020-08-01R007Afstyla, Solchayn351(a)RxCSL Behring Lengnau AG

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-06-01001Afstyla351(a)RxLicensed2016-05-25
2023-06-01002Afstyla351(a)RxLicensed2016-05-25
2023-06-01003Afstyla351(a)RxLicensed2016-05-25
2023-06-01004Afstyla351(a)RxLicensed2016-05-25
2023-06-01005Afstyla351(a)RxLicensed2016-05-25
2023-06-01006Afstyla351(a)RxLicensed2017-03-31
2023-06-01007Afstyla351(a)RxLicensed2017-03-31
2020-08-01001Afstyla, Solchayn351(a)RxLicensed2016-05-25
2020-08-01002Afstyla, Solchayn351(a)RxLicensed2016-05-25
2020-08-01003Afstyla, Solchayn351(a)RxLicensed2016-05-25
2020-08-01004Afstyla, Solchayn351(a)RxLicensed2016-05-25
2020-08-01005Afstyla, Solchayn351(a)RxLicensed2016-05-25
2020-08-01006Afstyla, Solchayn351(a)RxLicensed2017-03-31
2020-08-01007Afstyla, Solchayn351(a)RxLicensed2017-03-31